Navegar

Colección

Datos Estadísticas

Artículo

Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

Background: While breast cancer (BC) is the major cause of death among women worldwide, there is no guarantee of better patient survival because many of these patients develop primarily metastases, despite efforts to detect it in its early stages. Bone metastasis is a common complication that occurs in 65-80 % of patients with disseminated disease, but the molecular basis underlying dormancy, dissemination and establishment of metastasis is not understood. Our objective has been to evaluate simultaneously osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), stromal cell-derived factor-1 (SDF-1), and their receptors (R) in 2 human BC cell lines, MDA-MB-231 and MCF-7.Methods: OPG, RANKL, TRAIL and SDF-1 expression and release, in addition to the expression of their receptors has been investigated using immunofluorescence, immunocytochemistry and ELISA analyses.Results: MCF-7 cells released higher levels of OPG in conditioned media (CM) than MDA-MB-231 cells; 100 % of both types of cell expressed OPG, RANKL, TRAIL and SDF-1. Moreover, 100 % in both lines expressed membrane RANKL and RANK, whereas only 50 % expressed CXCR4. Furthermore, 100 % expressed TRAIL-R1 and R4, 30-50 % TRAIL-R2, and 40-55 % TRAIL-R3.Conclusions: MCF-7 and MDA-MB-231 cells not only released OPG, but expressed RANKL, TRAIL and SDF-1. The majority of the cells also expressed RANK, CXCR4 and TRAIL-R. Since these ligands and their receptors are implicated in the regulation of proliferation, survival, migration and future bone metastasis during breast tumor progression, assessment of these molecules in tumor biopsies of BC patients could be useful in identifying patients with more aggressive tumors that are also at risk of bone metastasis, which may thus improve the available options for therapeutic intervention. © 2012 Labovsky et al.; licensee BioMed Central Ltd.

Registro:

Documento: Artículo
Título:Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines
Autor:Labovsky, V.; Vallone, V.B.F.; Martinez, L.M.; Otaegui, J.; Chasseing, N.A.
Filiación:Laboratorio de Inmuno-Hematología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina
Consejo Nacional de Investigaciones, Científicas y Técnicas (CONICET), Buenos Aires, Argentina
Agencia Nacional de Promoción Científica y Tecnológica, Buenos Aires, Argentina
Vuelta de Obligado 2490, CP 1428, Buenos Aires, Argentina
Palabras clave:Breast cancer cells; OPG; RANKL; SDF-1; TRAIL; chemokine receptor CXCR4; death receptor 4; osteoclast differentiation factor; osteoprotegerin; receptor activator of nuclear factor kappa B; receptor protein; stromal cell derived factor 1; tumor necrosis factor related apoptosis inducing ligand; tumor necrosis factor related apoptosis inducing ligand receptor; article; bone metastasis; breast cancer; cancer cell culture; cancer risk; cancer survival; cell migration; cell proliferation; cell strain MCF 7; cell strain MDA MB 231; cell survival; controlled study; enzyme linked immunosorbent assay; human; human cell; immunocytochemistry; immunofluorescence; protein expression
Año:2012
Volumen:12
DOI: http://dx.doi.org/10.1186/1475-2867-12-29
Título revista:Cancer Cell International
Título revista abreviado:Cancer Cell Int.
ISSN:14752867
CODEN:CCIAC
CAS:chemokine receptor CXCR4, 188900-71-2; osteoclast differentiation factor, 200145-93-3; osteoprotegerin, 205944-50-9
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14752867_v12_n_p_Labovsky

Referencias:

  • Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., Estimating the world cancer burden: Globocan 2000 (2001) Int J Cancer, 94, pp. 153-156. , 10.1002/ijc.1440, 11668491
  • Bhatia, P., Sanders, M.M., Hansen, M.F., Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma (2005) Clin Cancer Res, 11, pp. 162-165
  • Kakarala, M., Wicha, M.S., Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy (2008) J Clin Oncol, 26, pp. 2813-2820. , Review, 10.1200/JCO.2008.16.3931, 2789399, 18539959
  • Patel, S.A., Heinrich, A.C., Reddy, B.Y., Srinivas, B., Heidaran, N., Rameshwar, P., Breast cancer biology: the multifaceted roles of mesenchymal stem cells (2008) J Oncol, 2008, p. 425895. , 2648640, 19277104
  • Moharita, A.L., Taborga, M., Corcoran, K.E., Bryan, M., Patel, P.S., Rameshwar, P., SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis (2006) Blood, 108, pp. 3245-3252. , 10.1182/blood-2006-01-017459, 16857992
  • Nicolin, V., Narducci, P., Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231 (2010) Acta Histochem, 112, pp. 189-192. , 10.1016/j.acthis.2008.09.011, 19058836
  • Jones, D.H., Nakashima, T., Sanchez, O.H., Kozieradzki, I., Komarova, S.V., Sarosi, I., Morony, S., Penninger, J.M., Regulation of cancer cell migration and bone metastasis by RANKL (2006) Nature, 440, pp. 692-696. , 10.1038/nature04524, 16572175
  • Lamoureux, F., Moriceau, G., Picarda, G., Rousseau, J., Trichet, V., Rédini, F., Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment (2010) Biochim Biophys Acta, 1805, pp. 17-24. , Review
  • Labrinidis, A., Liapis, V., le Thai, M., Atkins, G.J., Vincent, C., Hay, S., Sims, N.A., Evdokiou, A., Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? (2008) Blood, 111, pp. 5411-5412. , 10.1182/blood-2008-03-144261, 18502844
  • Thai le, M., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., Welldon, K., Coventry, B.J., Evdokiou, A., Apo2l/tumor necrosis factor-related apoptosisinducing ligand prevents breast cancer-induced bone destruction in a mouse model (2006) Cancer Res, 66, pp. 5363-5370. , 10.1158/0008-5472.CAN-05-4386, 16707463
  • Zauli, G., Melloni, E., Capitani, S., Secchiero, P., Role of full-length osteoprotegerin in tumor cell biology (2009) Cell Mol Life Sci, 66, pp. 841-851. , Review, 10.1007/s00018-008-8536-x, 19011755
  • Fili, S., Karalaki, M., Schaller, B., Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors (2009) Cancer Lett, 283, pp. 10-19. , Review
  • Tanaka, H., Mine, T., Ogasa, H., Taguchi, T., Liang, C.T., Expression of RANKL/OPG during bone remodeling in vivo (2011) Biochem Biophys Res Commun, 411, pp. 690-694. , 10.1016/j.bbrc.2011.07.001, 21771583
  • Buckle, C.H., Neville-Webbe, H.L., Croucher, P.I., Lawson, M.A., Targeting RANK/RANKL in the treatment of solid tumours and myeloma (2010) Curr Pharm Des, 16, pp. 1272-1283. , Review, 10.2174/138161210791034021, 20166980
  • Stanisławowski, M., Kmieć, Z., The participation of RANK, RANKL and OPG in tumor osteolysis (2009) Postepy Hig Med Dosw (Online), 63, pp. 234-241. , Polish
  • Canon, J.R., Roudier, M., Bryant, R., Morony, S., Stolina, M., Kostenuik, P.J., Dougall, W.C., Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis (2008) Clin Exp Metastasis, 25, pp. 119-129. , 10.1007/s10585-007-9127-1, 18064531
  • Holland, P.M., Miller, R., Jones, J., Douangpanya, H., Piasecki, J., Roudier, M., Dougall, W.C., Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis (2010) Cancer Biol Ther, 9, pp. 539-550. , 10.4161/cbt.9.7.11266, 20150760
  • Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., Diamond, P., Evdokiou, A., Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo (2011) J Bone Miner Res, 26, pp. 630-643. , 10.1002/jbmr.244, 20818644
  • LeBlanc, H.N., Ashkenazi, A., Apo2L/TRAIL and its death and decoy receptors (2003) Cell Death Differ, 10, pp. 66-75. , Review, 10.1038/sj.cdd.4401187, 12655296
  • Takeda, K., Stagg, J., Yagita, H., Okumura, K., Smyth, M.J., Targeting death-inducing receptors in cancer therapy (2007) Oncogene, 26, pp. 3745-3757. , Review, 10.1038/sj.onc.1210374, 17530027
  • Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M.J., Okumura, K., TRAIL and its receptors as targets for cancer therapy (2004) Cancer Sci, 95, p. 777. , Review, 10.1111/j.1349-7006.2004.tb02181.x, 15504243
  • Ashkenazi, A., Holland, P., Eckhardt, S.G., Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) (2008) J Clin Oncol, 26, pp. 3621-3630. , Review, 10.1200/JCO.2007.15.7198, 18640940
  • Kruyt, F.A., TRAIL and cancer therapy (2008) Cancer Lett, 263, pp. 14-25. , Review, 10.1016/j.canlet.2008.02.003, 18329793
  • Zhang, Y., Zhang, B., TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5 (2008) Mol Cancer Res, 6, pp. 1861-1871. , 10.1158/1541-7786.MCR-08-0313, 19074831
  • Cui, D.D., Huang, Y., Mao, S.H., Chen, S.C., Qiu, M., Ji, L.L., Yi, C., Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7 (2009) Braz J Med Biol Res, 42, pp. 854-862
  • Lacour, S., Hammann, A., Wotawa, A., Corcos, L., Solary, E., Dimanche-Boitrel, M.T., Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis (2001) Cancer Res, 61, pp. 1645-1651
  • Furusato, B., Mohamed, A., Uhlén, M., Rhim, J.S., CXCR4 and cancer (2010) Pathol Int, 60, pp. 497-505. , Review, 10.1111/j.1440-1827.2010.02548.x, 20594270
  • Huang, M., Li, Y., Zhang, H., Nan, F., Breast cancer stromal fibroblasts promote the generation of CD44 + CD24- cells through SDF-1/CXCR4 interaction (2010) J Exp Clin Cancer Res, 29, p. 80. , 10.1186/1756-9966-29-80, 2911413, 20569497
  • Kobayashi, T., Tsuda, H., Moriya, T., Yamasaki, T., Kikuchi, R., Ueda, S., Omata, J., Matsubara, O., Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis (2010) Breast Cancer Res Treat, 123, pp. 733-745. , 10.1007/s10549-009-0672-y, 20020198
  • Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Zlotnik, A., Involvement of chemokine receptors in breast cancer metastasis (2001) Nature, 410, pp. 50-56. , 10.1038/35065016, 11242036
  • Salvucci, O., Yao, L., Villalba, S., Sajewicz, A., Pittaluga, S., Tosato, G., Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1 (2002) Blood, 99, pp. 2703-2711. , 10.1182/blood.V99.8.2703, 11929756
  • Wang, Z., Ma, Q., Liu, Q., Yu, H., Zhao, L., Shen, S., Yao, J., Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway (2008) Br J Cancer, 99, pp. 1695-1703. , 10.1038/sj.bjc.6604745, 2584946, 19002187
  • Balkwill, F., Cancer and the chemokine network (2004) Nat Rev Cancer, 4, pp. 540-550. , Review, 10.1038/nrc1388, 15229479
  • Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., Piwnica-Worms, D., Luker, G.D., CXCR4 regulates growth of both primary and metastatic breast cancer (2004) Cancer Res, 64, pp. 8604-8612. , 10.1158/0008-5472.CAN-04-1844, 15574767
  • Rhodes, L.V., Short, S.P., Neel, N.F., Salvo, V.A., Zhu, Y., Elliott, S., Wei, Y., Burow, M.E., Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer (2011) Cancer Res, 71, pp. 603-613. , 10.1158/0008-5472.CAN-10-3185, 3140407, 21123450
  • Kang, H., Watkins, G., Parr, C., Douglas-Jones, A., Mansel, R.E., Jiang, W.G., Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer (2005) Breast Cancer Res, 7, pp. R402-410. , 10.1186/bcr1022, 1175055, 15987445
  • Lapteva, N., Yang, A.G., Sanders, D.E., Strube, R.W., Chen, S.Y., CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo (2005) Cancer Gene Ther, 12, pp. 84-89. , 10.1038/sj.cgt.7700770, 15472715
  • Schrader, A.J., Lechner, O., Templin, M., Dittmar, K.E., Machtens, S., Mengel, M., Probst-Kepper, M., Lauber, J., CXCR4/CXCL12 expression and signalling in kidney cancer (2002) Br J Cancer, 86, pp. 1250-1256. , 10.1038/sj.bjc.6600221, 2375348, 11953881
  • Corcoran, K.E., Trzaska, K.A., Fernandes, H., Bryan, M., Taborga, M., Srinivas, V., Packman, K., Rameshwar, P., Mesenchymal stem cells in early entry of breast cancer into bone marrow (2008) PLoS One, 3, pp. e2563. , 10.1371/journal.pone.0002563, 2430536, 18575622
  • Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A.M., Silberstein, L.E., Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors (2006) Stem Cells, 24, pp. 1030-1041. , 10.1634/stemcells.2005-0319, 16253981
  • Juarez, J., Bendall, L., Bradstock, K., Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis (2004) Curr Pharm Des, 10, pp. 1245-1259. , Review, 10.2174/1381612043452640, 15078139
  • Coleman, R.E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies (2001) Cancer Treat Rev, 27, pp. 165-176. , Review, 10.1053/ctrv.2000.0210, 11417967
  • Cross, S.S., Harrison, R.F., Balasubramanian, S.P., Lippitt, J.M., Evans, C.A., Reed, M.W., Holen, I., Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables (2006) J Clin Pathol, 59, pp. 716-720. , 10.1136/jcp.2005.030031, 1860414, 16489180
  • Neville-Webbe, H.L., Cross, N.A., Eaton, C.L., Nyambo, R., Evans, C.A., Coleman, R.E., Holen, I., Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis (2004) Breast Cancer Res Treat, 86, pp. 269-279
  • Van Poznak, C., Cross, S.S., Saggese, M., Hudis, C., Panageas, K.S., Norton, L., Coleman, R.E., Holen, I., Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours (2006) J Clin Pathol, 59, pp. 56-63. , 10.1136/jcp.2005.026534, 1860269, 16394281
  • Hofbauer, L.C., Rachner, T., Singh, S.K., Fatal attraction: why breast cancer cells home to bone (2008) Breast Cancer Res, 10, p. 101. , 10.1186/bcr1848, 2374958, 18226190
  • Santini, D., Schiavon, G., Vincenzi, B., Gaeta, L., Pantano, F., Russo, A., Ortega, C., Tonini, G., Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients (2011) PLoS One, 6, pp. e19234. , 10.1371/journal.pone.0019234, 3084800, 21559440
  • Brunetti, G., Oranger, A., Mori, G., Sardone, F., Pignataro, P., Coricciati, M., Napoli, N., Colucci, S., TRAIL effect on osteoclast formation in physiological and pathological conditions (2011) Front Biosci (Elite Ed), 3, pp. 1154-1161
  • Colucci, S., Brunetti, G., Cantatore, F.P., Oranger, A., Mori, G., Pignataro, P., Tamma, R., Grano, M., The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis (2007) Apoptosis, 12, pp. 1623-1632. , 10.1007/s10495-007-0095-3, 17558561
  • Romieu-Mourez, R., François, M., Boivin, M.N., Bouchentouf, M., Spaner, D.E., Galipeau, J., Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype (2009) J Immunol, 182, pp. 7963-7973. , 10.4049/jimmunol.0803864, 19494321
  • Fernández Vallone, V., Choi, H., Martinez, L.M., Labovsky, V., Batagelj, E., Dimase, F., Feldman, L., Chasseing, N.A., Osteoclastogenesis process in bone marrow of untreated advanced breast cancer patients [abstract] (2010) Program and Proceedings, 105, pp. B34
  • Martinez, L.M., Labovsky, V., Fernández Vallone VB, Bordenave RH, Feldman L, Chasseing NA: MCS and breast tumor cells [abstract] (2010) Program and Proceedings, 86, pp. A114
  • Velasco, C.R., Colliec-Jouault, S., Redini, F., Heymann, D., Padrines, M., Proteoglycans on bone tumor development (2010) Drug Discovery Today, 15, pp. 553-560. , Review, 10.1016/j.drudis.2010.05.009, 20553958
  • Baud'huin, M., Ruiz-Velasco, C., Jego, G., Charrier, C., Gasiunas, N., Gallagher, J., Maillasson, M., Heymann, D., Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption (2011) Eur J Cell Biol, 90, pp. 49-57. , 10.1016/j.ejcb.2010.08.001, 20970218
  • Holen, I., Shipman, C.M., Role of osteoprotegerin (OPG) in cancer (2006) Clin Sci (Lond), 110, pp. 279-291. , Review
  • Kapoor, P., Suva, L.J., Welch, D.R., Donahue, H.J., Osteoprotegrin and the bone homing and colonization potential of breast cancer cells (2008) J Cell Biochem, 103, pp. 30-41. , 10.1002/jcb.21382, 17471510
  • Brown, J.M., Zhang, J., Keller, E.T., Opg, RANKl, and RANK in cancer metastasis: expression and regulation (2004) Cancer Treat Res, Review, pp. 149-172. , Review
  • Patsialou, A., Wyckoff, J., Wang, Y., Goswami, S., Stanley, E.R., Condeelis, J.S., Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor (2009) Cancer Res, 69, pp. 9498-9506. , 10.1158/0008-5472.CAN-09-1868, 2794986, 19934330
  • Ibrahim, T., Sacanna, E., Gaudio, M., Mercatali, L., Scarpi, E., Zoli, W., Serra, P., Amadori, D., Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients (2011) Clin Breast Cancer, 11, pp. 369-375. , 10.1016/j.clbc.2011.05.001, 21764390
  • Ponte, A.L., Marais, E., Gallay, N., Langonné, A., Delorme, B., Hérault, O., Charbord, P., Domenech, J., The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities (2007) Stem Cells, 25, pp. 1737-1745. , 10.1634/stemcells.2007-0054, 17395768
  • Sanliogliu, A.D., Korcum, A.F., Pestereli, E., Erdogan, G., Karaveli, S., Savas, B., Griffith, T.S., Sanlioglu, S., TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma (2007) Int J Radiat Oncol Biol Phys, 69, pp. 716-723. , 10.1016/j.ijrobp.2007.03.057, 17512128
  • Kimberley, F.C., Screaton, G.R., Following a TRAIL: update on a ligand and its five receptors (2004) Cell Res, 14, pp. 359-372. , Review, 10.1038/sj.cr.7290236, 15538968
  • Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., Micheau, O., Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2 (2006) Mol Cell Biol, 26, pp. 7046-7055. , 10.1128/MCB.00520-06, 1592888, 16980609

Citas:

---------- APA ----------
Labovsky, V., Vallone, V.B.F., Martinez, L.M., Otaegui, J. & Chasseing, N.A. (2012) . Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell International, 12.
http://dx.doi.org/10.1186/1475-2867-12-29
---------- CHICAGO ----------
Labovsky, V., Vallone, V.B.F., Martinez, L.M., Otaegui, J., Chasseing, N.A. "Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines" . Cancer Cell International 12 (2012).
http://dx.doi.org/10.1186/1475-2867-12-29
---------- MLA ----------
Labovsky, V., Vallone, V.B.F., Martinez, L.M., Otaegui, J., Chasseing, N.A. "Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines" . Cancer Cell International, vol. 12, 2012.
http://dx.doi.org/10.1186/1475-2867-12-29
---------- VANCOUVER ----------
Labovsky, V., Vallone, V.B.F., Martinez, L.M., Otaegui, J., Chasseing, N.A. Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int. 2012;12.
http://dx.doi.org/10.1186/1475-2867-12-29